Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($10.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.77) by ($8.42), FiscalAI reports. The business had revenue of $8.00 million during the quarter, compared to the consensus estimate of $6.00 million.
Jasper Therapeutics Price Performance
Shares of JSPR opened at $10.34 on Wednesday. Jasper Therapeutics has a 1-year low of $9.25 and a 1-year high of $72.60. The stock has a market cap of $11.48 million, a PE ratio of -0.43 and a beta of 3.30. The firm has a fifty day moving average price of $16.38 and a 200 day moving average price of $23.78.
Analysts Set New Price Targets
Several brokerages have recently weighed in on JSPR. Rodman & Renshaw reissued a “buy” rating on shares of Jasper Therapeutics in a research report on Tuesday. Piper Sandler restated an “overweight” rating on shares of Jasper Therapeutics in a research note on Tuesday. Wall Street Zen downgraded Jasper Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating on shares of Jasper Therapeutics in a research note on Tuesday, August 18th. Finally, William Blair started coverage on shares of Jasper Therapeutics in a research note on Wednesday, October 14th. They issued an “outperform” rating on the stock. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $220.00.
View Our Latest Research Report on Jasper Therapeutics
About Jasper Therapeutics
Jasper Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for conditions involving blood-forming stem cells and mast cells. Its research focuses on c-Kit, also known as CD117, a protein found on these cells. The company’s lead investigational drug, briquilimab (formerly JSP191), is a monoclonal antibody that targets c-Kit. Jasper has studied briquilimab as a conditioning treatment for stem cell transplantation and gene therapy, and is evaluating it for mast cell-mediated diseases, including chronic spontaneous urticaria.
Featured Stories
- Five stocks we like better than Jasper Therapeutics
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
